González GR, Bologna MR, Mosqueda TA, Molina FN, Muñoz GJR, Farfán ME, Domínguez MH

Language: Spanish
References: 22
Page: 204-209
PDF size: 177.43 Kb.

ABSTRACT

Abstarct: Angiogenesis is an important event for the tumoral growth and progression. The vascular endothelial growth factor (VEGF) is the most important factor in the vascular neoformation, and the increase on its expression is associated with tumoral progression and worse prognosis in many different malignant tumors.
Objective: To evaluate the expression of VEGF-A and its receptor KDR/VEGF-2 in papillary thyroid carcinoma (CPT) larger and smaller than 10mm, with and without extracapsular extension (CPT-E and CPT-NE).
Methods: The expression of VEGF-A and KDR was studied with tissular microarray (TMA) in 62 cases of CPT-E and CPT-NE larger and smaller than 10mm. The positivity of VEGF-A and KDR was predominantly citoplasmatic, and it was evaluated in (-), (+), and (++).
Results: The expression of VEGF-A was very similar in CPT-E and CPT-NE with no statistical significance between tumoral size and between CPT-E and CPT-NE, but the expression intensity was harder for CPT-E >10mm, while the expression of KDR was more frequently observed in CPT-NE ≤10mm, the intensity was similar for both groups and sizes.
Conclusion: The results obtained correlate with the results publicated before, nevertheless, there are no publicated studies related with extracapsular extension and correlating VEGF-A and KDR. The intensity of the expression of VEGF-A was harder in CPT-E >10mm, while the expression intensity of KDR was similar between both groups concluding that the overexpression of VEGF-A, not the same for KDR, may be related to the extracapsular invasion, and because of that represents a worse prognosis.

REFERENCES

1. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y. S100A4 (Mts1) gene overexpression is associated with invasionand metastasis of papillary thyroid carcinoma. Br J Cancer 2005;93:1277-84.

2. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805-28.

3. McWilliams RR, Giannini C, Hay ID, Atkinson JL, et al. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 2003;98:356-62.

4. Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007;38:212-9.

5. Patel VA, Hill DJ, Eggo MC, Sheppard MC, et al. Changes in the immunohistochemical localization of fibroblast growth factor-2, transforming growth factor-beta-1 and thrombospondin-1 are associated with early abgiogenic events in the hyperplastic rat thyroid. J Endocrin 1996;148:485-99.

6. Sato K, Yamazaki K, Shizume K, Kanaji Y, et al. Stimulation of thyroid-stimulating hormone and Graves’ immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995;96:1295-302.

7. Shpitzer T, Feinmesser M, Stern Y, Feinmesser R. Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 1996;63:95- 98.

8. Ziche M, Magglione D, Ribatti D, Morbidelli L, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997;76:517-31.

9. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1- 30.

10. Muller YA, Li B, Christinger HW, Hans W, et al. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997;94:7192-7

11. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.

12. Alon T, Hemo I, Itin A, Pe'er J, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-8.

13. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273:13313-6.

14. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Seminars in Cancer Biology 1999;9:211-20.

15. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353- 64.

16. Soh EY, Duh QY, Sobhi SA, Young DM, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82:3741-7.

17. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. 1st ed. Lyon: IARC Press, 2004.

18. Pan CC, Chen PC, Chiang H. An easy method for manual construction of high-density tissue arrays. Appl Immunohistochem Mol Morpho 2004;12:370-2.

19. Götte M, Kerting C, Radke I, Kiesel L, Wülfing P. An expression signature of syndecan-1 (CD138). E- cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007;9:R8.

20. Jebreel A, England J, Bedford K, Murphy J, et al. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Path 2007;88:271-7.

21. Lantuéjoul S, Constantin B, Drabkin H, Brambilla C, et al. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003;200:336- 47.

22. Lennard CM, Patel A, Wilson J, Reinhardt B, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001;129:552-8.